CATALOGO DEI PRODOTTI DELLA RICERCA

BONIFACIO, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.963
EU - Europa 9.132
AS - Asia 7.577
SA - Sud America 1.155
Continente sconosciuto - Info sul continente non disponibili 333
AF - Africa 208
OC - Oceania 55
AN - Antartide 1
Totale 30.424
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.648
RU - Federazione Russa 3.560
SG - Singapore 2.775
CN - Cina 2.296
GB - Regno Unito 1.611
IT - Italia 1.161
BR - Brasile 898
HK - Hong Kong 727
VN - Vietnam 665
DE - Germania 551
SE - Svezia 492
FR - Francia 474
IE - Irlanda 417
FI - Finlandia 308
KR - Corea 242
BD - Bangladesh 198
IN - India 161
CA - Canada 160
UA - Ucraina 122
NL - Olanda 99
AR - Argentina 92
ID - Indonesia 78
MX - Messico 74
PL - Polonia 69
JP - Giappone 66
TR - Turchia 61
AU - Australia 49
ES - Italia 46
BE - Belgio 43
IQ - Iraq 42
CO - Colombia 41
NG - Nigeria 40
AT - Austria 36
EC - Ecuador 33
VE - Venezuela 33
ZA - Sudafrica 33
PK - Pakistan 28
UZ - Uzbekistan 25
CL - Cile 24
IR - Iran 24
MA - Marocco 23
TG - Togo 22
PH - Filippine 21
MY - Malesia 18
TN - Tunisia 18
RO - Romania 16
AZ - Azerbaigian 15
GR - Grecia 15
NP - Nepal 15
DZ - Algeria 14
JM - Giamaica 14
JO - Giordania 14
SA - Arabia Saudita 14
CZ - Repubblica Ceca 13
BJ - Benin 12
DK - Danimarca 12
PE - Perù 12
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
CR - Costa Rica 11
LT - Lituania 11
KZ - Kazakistan 10
PY - Paraguay 10
EG - Egitto 9
HN - Honduras 9
IL - Israele 8
KE - Kenya 8
TT - Trinidad e Tobago 8
BO - Bolivia 7
CG - Congo 7
NO - Norvegia 7
OM - Oman 7
RS - Serbia 7
SI - Slovenia 7
AL - Albania 6
KG - Kirghizistan 6
LV - Lettonia 6
NI - Nicaragua 6
TH - Thailandia 6
BH - Bahrain 5
EE - Estonia 5
ET - Etiopia 5
NZ - Nuova Zelanda 5
PT - Portogallo 5
QA - Qatar 5
SY - Repubblica araba siriana 5
TW - Taiwan 5
UY - Uruguay 5
BY - Bielorussia 4
EU - Europa 4
GT - Guatemala 4
HU - Ungheria 4
LK - Sri Lanka 4
PA - Panama 4
PR - Porto Rico 4
SV - El Salvador 4
AM - Armenia 3
BS - Bahamas 3
DO - Repubblica Dominicana 3
GE - Georgia 3
Totale 30.037
Salva come PNG Salva come JPEG
Città #
Ashburn 1.573
Singapore 1.402
Southend 1.303
San Jose 1.276
Moscow 1.160
Dallas 1.014
Chandler 968
Hong Kong 714
Beijing 532
Council Bluffs 522
Woodbridge 505
Dublin 415
Verona 412
The Dalles 403
Ann Arbor 329
Houston 275
Jacksonville 270
New York 243
Los Angeles 206
Wilmington 198
Ho Chi Minh City 194
Lawrence 172
Princeton 172
Santa Clara 151
Hanoi 141
Jinan 133
Nanjing 123
Shenyang 123
Buffalo 105
Munich 98
São Paulo 92
Helsinki 89
Redmond 88
Columbus 79
Milan 78
Redondo Beach 78
Sindelfingen 78
Hebei 76
Tianjin 69
Chicago 61
Tokyo 60
Warsaw 58
Orem 55
Zhengzhou 54
Montreal 52
Bologna 49
Changsha 49
Rome 49
London 48
Falls Church 46
Nanchang 46
Jakarta 45
Taizhou 45
Fuzhou 44
Ningbo 44
Guangzhou 43
Redwood City 43
Atlanta 41
Brussels 41
Hangzhou 41
Dong Ket 40
Nuremberg 39
Seattle 39
Chennai 38
Frankfurt am Main 38
Haikou 37
Phoenix 37
San Francisco 37
Turku 37
Denver 36
Seoul 36
Norwalk 32
Toronto 32
Rio de Janeiro 31
Abuja 30
Mexico City 29
Amsterdam 28
Kent 28
Belo Horizonte 27
Jiaxing 27
Boston 26
Perth 26
Boardman 25
Taiyuan 25
Johannesburg 24
Stockholm 24
Tashkent 24
Poplar 23
Falkenstein 22
Lomé 22
Brooklyn 21
Groningen 21
Shanghai 21
Washington 19
Da Nang 18
Naples 18
Brasília 17
Vienna 17
Charlotte 16
Dearborn 16
Totale 17.976
Salva come PNG Salva come JPEG
Nome #
Epidemiology of mastocytosis in adults based on a multidisciplinary diagnostic approach. 341
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 271
CD66b-CD64dimCD115- cells in the human bone marrow represent neutrophil-committed progenitors 271
A study of the crosstalk between CD30 and CXCR4 267
Role of GSK-3 signalling in non-promyelocitic acute myeloid leukemia (AML) cell response to chemotherapy 261
Notch singalling inhibition as a multi-target therapy to overcome bone marrow microenvironment-mediated drug resistance in AML 258
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 254
Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia 252
Role of Wnt/β-Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy 252
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 246
ALK-positive anaplastic large cell lymphoma with PAX-5 expression: report of a case 244
A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma 242
Inhibition of GSK-3 Signalling Enhances Sensitivity of Non-Promyelocitic Acute Myeloid Leukemia (AML) Cell to Chemotherapy 241
Clonal mast cell disorders limited to bone marrow: not a negligible disease. 239
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 236
Rational of targeting WNT/beta-catenin signaling in acute myeloid leukemia (AML) 236
Inhibition of Notch signalling overcomes bone marrow stromal-mediated anti-apoptotic and chemoresistance effects in AML. 234
Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. 232
Autoimmune complications are frequent in splenic and nodal marginal zone lymphomas 231
A simple score predicts clonal mast cell disorders in patients with systemic reactions to Hymenoptera venom without skin lesions 220
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia and may provide prognostic informations 220
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 219
CXCL12 and [N33A]CXCL12 in 5637 and HeLa Cells: Regulating HER1 Phosphorylation via Calmodulin/Calcineurin 218
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 215
Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels 214
Value of flow cytometry in the diagnosis of indolent systemic mastocytosis. 213
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis 212
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 210
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 206
Inhibition of Notch signaling enhances chemosensitivity in B cell precursor acute lymphoblastic leukemia 199
Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis. 197
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 196
α-bisabolol is an effective proapoptotic agent against BCR-ABL+ cells in synergism with Imatinib and Nilotinib 195
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 195
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 193
Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements 193
Back to life – Living, treating, managing myelofibrosis: the burden of illness for patients and their families 191
Characterization of a new B-ALL cell line with constitutional defect of the Notch signaling pathway 191
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 191
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 191
A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years’ Experience of the GISM Network 191
The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis 189
TP53 mutations in adult acute lymphoblastic leukemia (ALL) are relatively frequent in molecularly negative case of both B- and T-lineage and correlate with poor response to induction therapy 188
BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL) 188
The Sesquiterpene Oil {alpha}-Bisabolol Induces Apoptosis of B-Chronic Lymphocytic Leukemia Primary Cells 187
Improved detection of the C-KIT D816V mutation using allele-specific arms real time PCR assay allows a finer recognition of patients with indolent systemic mastocytosis. 187
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 186
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 186
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 186
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 185
Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia 185
Uncovering two neutrophil-committed progenitors that immediately precede promyelocytes during human neutropoiesis 182
Plasmacytoid dendritic cell leukemia: a rapidly evolving disease presenting with skin lesions sensitive to radiotherapy plus hyperthermia. 182
Short-term, intensive chemotherapy regimen is equally effective in Burkitt lymphoma (BL) and in the novel WHO 2008 entity “B-cell lymphoma intermediate between DLBCL and BL". 182
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 181
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 181
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 180
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 179
Molecular “warning” CML patients: a retrospective study of Gruppo Triveneto LMC. 179
Bone Disease in Mastocytosis 178
Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis 178
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells 176
Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis 174
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis 173
A critical comparison of Sokal, Euro, and Eutos risk scores in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. 172
Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis 172
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements 169
The impact of a 7-day prednisone (PDN) pretreatment in adult (less than 60y) acute lymphoblastic leukemia (ALL) therapy: results of LAL2000 vs LAL0496. 169
Unexpected subacute leucoencephalopathy following intrathecal methotrexate and cytarabine administration in a patient homozygous for MTHFR 677C→T polymorphism. 169
EUTOS Score Identifies Cases with Poor Outcome in Patients with Early Chronic Phase Chronic Myeloid Leukemia, Though Not Predictive for Optimal Response to Imatinib 167
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 166
Serum tryptase levels differently change over time in indolent systemic mastocytosis with or without skin lesions. 166
Ultra-deep sequencing (UDS) allows more sensitive detection of the D816V and other KIT gene mutations in systemic mastocytosis 165
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 165
Regulative loop between beta-catenin and protein tyrosine phosphatase receptor type gamma (PTPRG) in chronic myeloid leukemia 165
Mitochondrial-Mediated Apoptosis by the Sesquiterpene Oil {alpha}-Bisabolol and Its Synergism with Imatinib and Nilotinib In BCR-ABL+ Cells. 164
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 164
Systemic mastocytosis: a muldisciplinary approach (Review) [Lamastocitosi sistemica: Un approccio multidiscliplinare] 163
Combination of EUTOS score and 3-months BCR-ABL transcript level identifies a distinct subgroup of ECP-CML patients with high risk of non optimal response and imatinib discontinuation. 162
Modified HyperCVAD and rituximab for the treatment of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. 162
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 161
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 160
Sesquiterpene α-bisabolol, which binds to Bid in lipid rafts, induces apoptosis in BCR/ABL+ cell lines through membrane depolarization. 158
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 158
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 157
High incidence of autoimmune complications in 82 patients with non-MALT marginal zone lymphomas. 155
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 155
Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association 154
PBX/E2A transcript positive B-lymphoblastic leukemia (B-ALL) presenting with bilateral renal and myocardial involvement: a case report. 152
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 152
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study 152
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 151
Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases 151
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors 150
Blastic plasmacytoid dendritic cell leukemia: preliminary results of a retrospective italian multicentric study. 149
Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases 148
BCR-ABL mutations in chronic myeloid leukemia (CML) patients (pts) with failure and warning to first- and second-lline tyrosine kinase inhibitor (TKI) therapy: what is the advantage of Next-Generation Sequencing (NGS) over conventional sequencing? 147
How patients perceive a switch from imatinib to nilotinib: results of a patient-centered analysis 147
Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia 147
International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study 146
Totale 19.180
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.418
article - articoli 76.256
book - libri 0
conference - conferenze 33.650
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 512
Totale 220.836
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022865 0 0 0 141 109 56 24 73 72 40 78 272
2022/20232.692 190 264 263 470 208 704 33 152 297 24 46 41
2023/20241.596 73 128 90 158 175 197 63 109 27 86 379 111
2024/20254.293 188 241 214 703 183 141 210 238 629 318 425 803
2025/202613.073 881 747 903 2.060 3.080 800 1.182 748 1.053 845 300 474
2026/20272.152 289 547 639 677 0 0 0 0 0 0 0 0
Totale 30.424